RxDoctor Payments Data

Surendra Gudapati, MD

Cardiovascular Disease · Mountain View, CANPI 1245262716

Payments from drug & device makers

$566in general payments, 2019–2025

Across 23 payments — averaging $24.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ironshore Pharmaceuticals Inc.$328
  • Abiomed$125
  • Abbott$70
  • Cordis US CORP.$20
  • Novo Nordisk$14
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$9

What the payments were for

  • Food & beverage$566100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$566 in reported general payments places this provider in the 25th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$356,960
Medicare patients
1,189
Services billed
3,746

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban366$529,853
XareltoRivaroxaban72$108,626
EntrestoSacubitril/Valsartan77$86,625
FarxigaDapagliflozin Propanediol61$69,251
JardianceEmpagliflozin42$48,645
JanuviaSitagliptin Phosphate17$25,994
OzempicSemaglutide18$16,415
NexletolBempedoic Acid13$15,995
Praluent PenAlirocumab18$15,130
Ezetimibe304$12,194
Atorvastatin Calcium778$7,687
Metoprolol Succinate358$5,619
Rosuvastatin Calcium374$5,287
Amiodarone Hcl59$5,098
Potassium Chloride84$4,812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$14$16,41518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Mountain View

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →